S-23 + YK-11 + LGD-4033 + 5a Hydroxy Laxogenin Transdermal

What is S-23 + YK-11 + LGD-4033 + 5a Hydroxy Laxogenin Transdermal?

Combining S-23, YK-11, LGD-4033, and 5a Hydroxy Laxogenin, this Transdermal is intended to improve muscular mass, strength, endurance, and recuperation in test models. Because androgen receptors (AR) are widely distributed throughout the body, this formula combines the actions of selective androgen receptor modulators (SARMs) with the protein synthesis-enhancing qualities of 5a Hydroxy Laxogenin, addressing a wider range of tissue targets.

Potential Benefits of the Stack

• SARMs (S-23, YK-11, and LGD-4033) and 5a Hydroxy Laxogenin may potentially boost protein synthesis and muscle growth in research subjects.
• S-23 and LGD-4033 may aid fat loss studies.
• 5a Hydroxy Laxogenin may minimize muscular fatigue and improve recovery in test models.

What are Selective Androgen Receptor Modulators (SARMs)?

How does S-23 work?

S-23 functions as a selective androgen receptor modulator (SARM) by binding to androgen receptors in the body, maximising anabolic activity in muscle and bone tissue, and reducing androgenic effects in other tissues. After binding to the androgen receptor, the S-23 complex translocates to the cell nucleus, where it recruits several cofactors and co-regulatory proteins to control gene expression [R].

S-23 may cure muscle wasting and osteoporosis by boosting muscle mass and bone density in clinical subjects. Tissue-selective anabolic treatment may have fewer negative effects than standard steroids.

S23 Investigations

• Potentially aids in fat loss research by promoting lean muscle mass and male contraceptive [R]

Safety and Side Effects

The side effects of S-23 include testosterone suppression, which can necessitate post-cycle therapy (Post-Research Recovery Protocol) to restore natural hormone levels in clinical subjects. Other potential side effects include mood swings, liver toxicity, and changes in lipid profiles [R], although comprehensive long-term safety data are lacking due to limited human studies.

How does YK11 work?

A androgen receptor (AR) partial agonist YK11 activates AR without an N/C interaction and significantly enhances essential myogenic regulatory factors (MRFs) in muscle tissue, promoting anabolic activity. It increases the levels of follistatin, a protein that suppresses myostatin. Myostatin is a growth factor that controls muscle growth; therefore, blocking it with YK-11 may lead to enhanced muscular development [R].

YK-11 acts as a partial androgen receptor (AR) agonist by increasing follistatin (FST) synthesis and targeting certain genes, such as myostatin (GDF8), thus increasing its ability to promote muscle growth and bone tissue development. YK-11’s myogenic actions entail NF-κB signaling, which has been shown to reduce muscle wasting during sepsis [R].

YK-11 Investigations

• Potential treatment of osteoporosis [R]
• Stimulates muscle growth while inhibiting myostatin[R]
• Promotes significant muscle hypertrophy that reverts muscle wasting during sepsis recovery and subdues the inflammatory environment [R].

Safety and Side Effects

YK-11 has yet to be tested in human clinical trials. However, its strong anabolic effects might also lead to severe hormonal imbalances, which are visible in some test subjects [R].

How does LGD-4033 (Ligandrol) work?

LGD-4033 mimics the actions of androgen, although it does not have the unfavorable side effects on the skin or prostate. Because of its selectivity, it is a desirable choice for studies looking for less risky anabolic advantages. Additionally, experiments conducted on animals showed strong selectivity for muscle over prostate and anabolic and anti-resorptive effects in bone [R].

Drug Investigations:

• Increases lean muscle mass in test subjects [R].
• It may improve osteoporotic bones [R],[R].
• Potential anabolic therapies for muscle loss are associated with aging, illness, or specific conditions like cancer, cachexia, and osteoporosis, paving the way for longer-term efficacy trials in older test subjects [R].

Safety and Side Effects

Clinical trials suggest that LGD-4033 is generally well-tolerated. It has a favorable pharmacokinetic profile and improved lean body mass, despite a brief period of no significant change in prostate-specific antigen levels. However, higher doses or long-term use may result in a reduction in natural testosterone production, necessitating a Post-Research Recovery Protocol[R].

What is 5 Alpha Hydroxy-laxogenin?

5α-hydroxylaxogenin is a synthetic derivative of a naturally occurring spirostane-type steroid, laxogenin, that shows androgenic potential. However, there is currently no solid evidence supporting the anabolic or androgenic activity of 5α-hydroxy-laxogenin [R].

How it works

In recent research, two in vitro bioassays were conducted to examine its androgenic potential. In human prostate cells, 5α-hydroxy-laxogenin transactivated the androgen receptor in a dose-dependent manner in both situations. It is interesting to note that at higher doses, it had agonistic effects but antagonistic properties at lower ones. These results imply that higher dosages of 5α-hydroxy-laxogenin might have androgenic properties, but more research is still needed to determine its safety and potential anabolic advantages [R].

5 alpha-hydroxy-laxogenin Investigations

• Possible anticancer activity in a two-stage lung carcinogenesis research. [R] [R].
• Potential to neutralize oxidative stress [R]
• It may contribute to muscle growth in subjects. [R]

Safety and Side Effects

Though 5 alpha-Hydroxy Laxogenin is advertised as an anabolic agent in dietary supplements, research evidence supporting its effects remains inadequate. The observed androgenic activity in human cells at greater concentrations suggests potential anabolic effects, but it also highlights the need for additional research to fully understand the risks and benefits.

Conclusion

S-23, YK-11, LGD-4033, and 5a Hydroxy Laxogenin are a stack of multicomponent SARMs that have the ability to optimize physical performance, strength, and muscle growth. Purerawz sells the S-23 + YK-11 + LGD-4033 + 5a Hydroxy Laxogenin Transdermal exclusively for research purposes. To further reduce the potential for adverse effects on natural hormone production, it is essential to follow an appropriate post-cycle treatment (Post-Research Recovery Protocol) protocol.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR LABORATORY AND RESEARCH USE ONLY. All clinical research must be conducted with the appropriate Institutional Review Board (IRB) oversight. All preclinical research must be conducted with oversight from the relevant Institutional Animal Care and Use Committee (IACUC), following the Animal Welfare Act (AWA) guidelines.

Our content is intended to be used and must be used for informational purposes only. It is essential to do your analysis and read research from Trusted Sources before making any purchase based on your circumstances. You should independently add research and verify any information that you find on our Website and wish to rely upon.

By completing and paying for your order, you agree to our Terms and Conditions. Customer satisfaction is our number one priority. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human usage. Stock is subject to availability